Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACAB Stock Forecast 2026-2027
$0.14
Current Price
$1.25M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ACAB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ACAB Price Momentum
+16.7%
1 Week Change
-6.7%
1 Month Change
-48.1%
1 Year Change
-96.7%
Year-to-Date Change
-98.1%
From 52W High of $7.34
+61.7%
From 52W Low of $0.09
📊 TOP ANALYST CALLS
Did ACAB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ACAB is one of their latest high-conviction picks.
Latest ACAB Stock Price Targets & Analyst Predictions
ACAB has shown a year-to-date change of -96.7% and a 1-year change of -48.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ACAB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACAB Analyst Ratings
0
Buy
0
Hold
0
Sell
ACAB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.14
Latest ACAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Abpro Holdings Inc. (ACAB) Competitors
The following stocks are similar to ACAB based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ACAB
Atlantic Coastal II
mkt cap
980,086
Abpro Holdings Inc. (ACAB) Financial Data
Valuation Metrics
Market Cap
$1.25M
Enterprise Value
$0
P/E Ratio
78.7x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.6%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
-33.1%
ROA
+7.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Abpro Holdings Inc. (ACAB) Business Model
About Abpro Holdings Inc.
What They Do
Develops next-generation antibody therapeutics.
Business Model
Abpro Holdings Inc. operates a biotechnology model focused on developing targeted antibody therapies for diseases, particularly in oncology and immunology. The company generates revenue through the advancement of its product candidates, which are designed to address unmet medical needs and are positioned for commercialization in the pharmaceutical market.
Additional Information
Founded in 2004 and based in Woburn, Massachusetts, Abpro's proprietary DiversImmune platform enhances its drug discovery capabilities. The company's portfolio includes several promising candidates, such as ABP-102, ABP-110, and ABP-201, aimed at treating various cancers and ocular diseases, contributing to advancements in therapeutic antibody research.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6
CEO
Mr. Jin Wook Suk
Country
United States
IPO Year
2022
Website
abpro.coAbpro Holdings Inc. (ACAB) Latest News & Analysis
Latest News
Quick Summary
Monteverde & Associates is investigating Atlantic Coastal Acquisition Corp. II (Nasdaq: ACAB) regarding its merger with Abpro Merger Sub Corp, where Abpro shares will convert to 2.06 ACAB shares.
Why It Matters
The investigation into Atlantic Coastal Acquisition Corp. II's merger could impact stock valuations, affecting shareholders' investments and market dynamics surrounding the deal.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) received a notice from Nasdaq for not filing its Q1 2024 report. This does not immediately affect its listing status.
Why It Matters
ACAB's failure to file its 10-Q raises compliance concerns, potentially impacting investor confidence and stock performance. Ongoing monitoring of its listing status is essential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atlantic Coastal Acquisition Corp. II has extended its business combination deadline by one month to November 19, 2023, after the Sponsor deposited $80,000 into its trust account.
Why It Matters
The extension of the business combination deadline indicates the company is still pursuing acquisition opportunities, which can affect investor confidence and potential returns.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced a term sheet for a business combination, expected to advance Abpro's antibody therapies for severe diseases.
Why It Matters
The merger between Abpro Corporation and Atlantic Coastal Acquisition Corp. II signals potential growth in the biotech sector, attracting investor interest in innovative therapies and SPAC opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Atlantic Coastal Acquisition Corp. II completed an IPO in January 2022, raising $300 million.
Why It Matters
The $300 million IPO by Atlantic Coastal Acquisition Corp. II indicates strong market interest, potentially signaling future investment opportunities and growth in the SPAC sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Atlantic Coastal Acquisition Corp. II will allow unit holders to separately trade shares of Series A common stock and warrants starting March 7, 2022. Only whole warrants will be traded.
Why It Matters
The separation of shares and warrants allows for more flexible trading options, potentially increasing liquidity and attracting more investors to Atlantic Coastal Acquisition Corp. II.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACAB Stock
What is Abpro Holdings Inc.'s (ACAB) stock forecast for 2026?
Analyst forecasts for Abpro Holdings Inc. (ACAB) are not currently available. The stock is trading at $0.14.
Is ACAB stock a good investment in 2026?
Analyst ratings for ACAB are not currently available. The stock is currently trading at $0.14. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACAB stock?
Price predictions from Wall Street analysts for ACAB are not currently available. The stock is trading at $0.14.
What is Abpro Holdings Inc.'s business model?
Abpro Holdings Inc. operates a biotechnology model focused on developing targeted antibody therapies for diseases, particularly in oncology and immunology. The company generates revenue through the advancement of its product candidates, which are designed to address unmet medical needs and are positioned for commercialization in the pharmaceutical market.
What is the highest forecasted price for ACAB Abpro Holdings Inc.?
Price targets from Wall Street analysts for ACAB are not currently available. The stock is trading at $0.14.
What is the lowest forecasted price for ACAB Abpro Holdings Inc.?
Price targets from Wall Street analysts for ACAB are not currently available. The stock is trading at $0.14.
What is the overall ACAB consensus from analysts for Abpro Holdings Inc.?
Analyst ratings for ACAB are not currently available. The stock is trading at $0.14.
How accurate are ACAB stock price projections?
Stock price projections, including those for Abpro Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 2:01 AM UTC